ATABAY, Elif Karaca, Carmen MECCA, Qi WANG, Chiara AMBROGIO, Ines MOTA, Nina PROKOPH, Giulia MURA, Cinzia MARTINENGO, Enrico PATRUCCO, Giulia LEONARDI, Jessica HOSSA, Achille PICH, Luca MOLOGNI, Carlo GAMBACORTI-PASSERINI, Laurence BRUGIERES, Birgit GEOERGER, Suzanne Dawn TURNER, Claudia VOENA, Taek-Chin CHEONG and Roberto CHIARLE. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK(+) anaplastic large cell lymphoma. Blood. Washington DC, USA: American Society of Hematology, 2022, vol. 139, No 5, p. 717-731. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood.2020008136.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK(+) anaplastic large cell lymphoma
Authors ATABAY, Elif Karaca, Carmen MECCA, Qi WANG, Chiara AMBROGIO, Ines MOTA, Nina PROKOPH, Giulia MURA, Cinzia MARTINENGO, Enrico PATRUCCO, Giulia LEONARDI, Jessica HOSSA, Achille PICH, Luca MOLOGNI, Carlo GAMBACORTI-PASSERINI, Laurence BRUGIERES, Birgit GEOERGER, Suzanne Dawn TURNER (826 United Kingdom of Great Britain and Northern Ireland, guarantor, belonging to the institution), Claudia VOENA, Taek-Chin CHEONG and Roberto CHIARLE.
Edition Blood, Washington DC, USA, American Society of Hematology, 2022, 0006-4971.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 20.300
RIV identification code RIV/00216224:14740/22:00127884
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1182/blood.2020008136
UT WoS 000773681200003
Keywords in English NPM-ALKSTAT3 ACTIVATIONLUNG-CANCERPROTEINKINASERECEPTORGROWTHIDENTIFICATIONSHP21B
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 11/1/2023 14:53.
Abstract
Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene. Targeting ALK using tyrosine kinase inhibitors (TKIs) is a therapeutic option in cases relapsed after chemotherapy, but TKI resistance may develop. By applying genomic loss-of-function screens, we identified PTPN1 and PTPN2 phosphatases as consistent top hits driving resistance to ALK TKIs in ALK(+) ALCL. Loss of either PTPN1 or PTPN2 induced resistance to ALK TKIs in vitro and in vivo. Mechanistically, we demonstrated that PTPN1 and PTPN2 are phosphatases that bind to and regulate ALK phosphorylation and activity. In turn, oncogenic ALK and STAT3 repress PTPN1 transcription. We found that PTPN1 is also a phosphatase for SHP2, a key mediator of oncogenic ALK signaling. Downstream signaling analysis showed that deletion of PTPN1 or PTPN2 induces resistance to crizotinib by hyperactivating SHP2, the MAPK, and JAK/STAT pathways. RNA sequencing of patient samples that developed resistance to ALK TKIs showed downregulation of PTPN1 and PTPN2 associated with upregulation of SHP2 expression. Combination of crizotinib with a SHP2 inhibitor synergistically inhibited the growth of wild-type or PTPN1/PTPN2 knock-out ALCL, where it reverted TKI resistance. Thus, we identified PTPN1 and PTPN2 as ALK phosphatases that control sensitivity to ALK TKIs in ALCL and demonstrated that a combined blockade of SHP2 potentiates the efficacy of ALK inhibition in TKI-sensitive and -resistant ALK(+) ALCL.
PrintDisplayed: 6/10/2024 21:05